Scarica l'app Stockscreener
42.90
0.28%
-0.345
Precedente Chiudi:
$43.24
Aprire:
$42.86
Volume 24 ore:
162.09K
Relative Volume:
0.22
Capitalizzazione di mercato:
$2.50B
Reddito:
$32.87M
Utile/perdita netta:
$674.31M
Rapporto P/E:
3.776
EPS:
11.36
Flusso di cassa netto:
$-330.11M
1 W Prestazione:
+0.09%
1M Prestazione:
+6.47%
6M Prestazione:
+43.26%
1 anno Prestazione:
-3.90%
Intervallo 1D:
$42.74
$44.10
Intervallo di 1 settimana:
$40.18
$44.10
Portata 52W:
$23.41
$62.58
Agios Pharmaceuticals Inc Stock (AGIO) Company Profile
Nome
Agios Pharmaceuticals Inc
Settore
Industria
Telefono
617-649-8600
Indirizzo
88 SIDNEY STREET, CAMBRIDGE, MA
Confronta AGIO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AGIO
Agios Pharmaceuticals Inc
|
42.98 | 2.52B | 32.87M | 674.31M | -330.11M | 11.36 |
|
VRTX
Vertex Pharmaceuticals Inc
|
423.65 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
638.50 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
443.80 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
824.69 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.38 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-24 | Iniziato | H.C. Wainwright | Buy |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-09-27 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-02-08 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-02-03 | Iniziato | Piper Sandler | Overweight |
| 2022-11-17 | Aggiornamento | Goldman | Sell → Neutral |
| 2022-07-27 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2021-12-03 | Iniziato | BofA Securities | Buy |
| 2021-07-30 | Downgrade | Goldman | Neutral → Sell |
| 2021-07-01 | Iniziato | Raymond James | Mkt Perform |
| 2021-06-10 | Iniziato | H.C. Wainwright | Buy |
| 2021-03-01 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-03-01 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2021-02-26 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2020-10-22 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2020-03-04 | Iniziato | Barclays | Equal Weight |
| 2019-11-26 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-09-23 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-05-23 | Ripresa | Goldman | Neutral |
| 2019-02-15 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2018-09-25 | Iniziato | Leerink Partners | Mkt Perform |
| 2018-05-23 | Iniziato | Citigroup | Buy |
| 2018-04-11 | Reiterato | Credit Suisse | Outperform |
| 2018-02-15 | Reiterato | Needham | Buy |
| 2018-02-15 | Reiterato | SunTrust | Buy |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Outperform |
| 2017-08-10 | Reiterato | Needham | Buy |
| 2017-08-08 | Reiterato | SunTrust | Buy |
| 2017-08-02 | Aggiornamento | Leerink Partners | Mkt Perform → Outperform |
| 2017-06-26 | Downgrade | Janney | Buy → Neutral |
| 2017-01-17 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2016-10-24 | Iniziato | Needham | Buy |
| 2016-06-13 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2016-05-18 | Reiterato | SunTrust | Buy |
Mostra tutto
Agios Pharmaceuticals Inc Borsa (AGIO) Ultime notizie
Agios (AGIO) Unveils Promising Mitapivat Data at ASH 2025 - GuruFocus
Agios (Nasdaq: AGIO) shows mitapivat data: 77.8% alpha-thal response; 30.5-week mean - Stock Titan
Will Agios Pharmaceuticals Inc. benefit from macro trendsJuly 2025 Volume & Fast Gaining Stock Reports - newser.com
How supply chain issues affect Agios Pharmaceuticals Inc. stockJuly 2025 Drop Watch & AI Optimized Trading Strategy Guides - newser.com
Is Agios Pharmaceuticals Inc. building a consolidation basePortfolio Risk Report & AI Driven Stock Movement Reports - newser.com
How Agios Pharmaceuticals Inc. (8AP) stock correlates with oil marketsEntry Point & AI Powered Market Entry Ideas - newser.com
What is HC Wainwright's Estimate for AGIO FY2025 Earnings? - MarketBeat
What earnings revisions data tells us about Agios Pharmaceuticals Inc.Entry Point & Smart Investment Allocation Insights - newser.com
Is it time to cut losses on Agios Pharmaceuticals Inc.Inflation Watch & Breakout Confirmation Alerts - newser.com
Can Agios Pharmaceuticals Inc. stock deliver sustainable ROERate Hike & Daily Stock Trend Reports - newser.com
What drives Agios Pharmaceuticals Inc stock priceMarket Capitalization Trends & High Return Capital Strategies - earlytimes.in
Published on: 2025-10-21 20:21:19 - earlytimes.in
Is Agios Pharmaceuticals Inc. (8AP) stock among top earnings playsMarket Volume Summary & Safe Capital Growth Trade Ideas - newser.com
Is Agios Pharmaceuticals Inc. stock supported by strong cash flowsStop Loss & Weekly High Return Opportunities - newser.com
Institutional scanner results for Agios Pharmaceuticals Inc.Bond Market & Weekly Chart Analysis and Trade Guides - newser.com
What data driven models say about Agios Pharmaceuticals Inc.’s future - newser.com
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Savvy Advisors Inc. Takes Position in Agios Pharmaceuticals, Inc. $AGIO - MarketBeat
Published on: 2025-11-02 02:45:06 - newser.com
Candlestick signals on Agios Pharmaceuticals Inc. stock todayQuarterly Market Summary & Reliable Price Action Trade Plans - newser.com
Agios Pharmaceuticals Q3 2025 Earnings Preview - MSN
Agios outlines Q4 2025 PYRUKYND milestones and anticipates U.S. thalassemia approval amid global expansion - MSN
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q3 2025 Earnings Call Transcript - Insider Monkey
RBC Capital Keeps Their Buy Rating on Agios Pharma (AGIO) - The Globe and Mail
Published on: 2025-11-01 04:26:21 - newser.com
Agios Pharmaceuticals’ Earnings Call: Growth and Challenges - MSN
AGIO's Q3 Loss Narrower Than Expected, Pyrukynd Drives Y/Y Revenues - sharewise.com
Agios Pharmaceuticals (NASDAQ:AGIO) Issues Quarterly Earnings Results, Beats Expectations By $0.15 EPS - MarketBeat
High Growth Tech Stocks In The US Market With Promising Potential - simplywall.st
Can Agios Pharmaceuticals Inc. stock surprise with earnings upsideGap Down & Comprehensive Market Scan Reports - newser.com
Agios Pharmaceuticals Inc Azioni (AGIO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Agios Pharmaceuticals Inc Azioni (AGIO) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Gheuens Sarah | Chief Medical Officer |
Oct 27 '25 |
Option Exercise |
25.01 |
3,302 |
82,583 |
65,029 |
| Gheuens Sarah | Chief Medical Officer |
Oct 27 '25 |
Sale |
43.92 |
3,302 |
145,024 |
61,727 |
0.03%
0.32%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):